| Oct. 2006 | Established a company aiming to develop new drugs based on the discovery of bone marrow multi-potent stem cell mobilization factors identified by Professor Katsuto Tamai of the Graduate School of Medicine, Osaka University. |
|---|---|
| Apr. 2007 | Started collaborative research with Osaka University. We have since continued to create intellectual property from the results of research. |
| Oct. 2008 | Won a research grant from Japan Science & Technology Agency (JST), Industry-Academic Collaborative Seed Innovation Program. |
| Dec. 2009 | Won a research grant from JST, “A-STEP (Adaptable and Seamless Technology Transfer Program through Target-driven R&D)” |
| Apr. 2010 | Transferred our head office to Saito Bio Incubator (Ibaraki City, Osaka Prefecture) and set up a laboratory there. Concluded a collaborative research contract with Shionogi & Co., Ltd. for research into bone marrow-derived stem cell mobilizing factor. |
| Nov. 2011 | Won a research grant from JST, “A-STEP (Adaptable and Seamless Technology Transfer Program through Target-driven R&D)” |
| June 2012 | Opened Kobe Lab in Port Island, Kobe. Expanded the capacity to perform drug efficacy tests using disease model animals. |
| July 2013 | Expanded the laboratory in Saito Bio Incubator, expanded animal experiment facilities and absorbed the function of Kobe Lab. |
| Dec. 2013 | Won a research grant from JST, “A-STEP (Adaptable and Seamless Technology Transfer Program through Target-driven R&D)”. |
| Apr. 2014 | Adopted as a joint research project of The Center of Medical Innovation and Translational Research (CoMIT), Osaka University Graduate School of Medicine. |
| May 2014 | Won a research grant from the New Energy and Industrial Technology Development Organization (NEDO), Innovation Commercialization Venture Support Project. |
| Nov. 2014 | Concluded a licensing contract with Shionogi & Co., Ltd. for HMGB1 peptides (Redasemtide). |
| Aug. 2015 | An investigator-initiated phase 1 clinical trial of Redasemtide started at Osaka University. |
| Dec. 2017 | An investigator-initiated phase 2 clinical trial of Redasemtide in patients with Dystrophic Epidermolysis Bullosa(DEB) started. |
| July 2018 | Changed our company name to StemRIM Inc. |
| Apr. 2019 | A corporate phase 2 clinical trial of Redasemtide in patients with Acute Ischemic Stroke started at Shionogi & Co., Ltd. |
| Aug. 2019 | Listed on the Tokyo Stock Exchange Mothers |
| Apr. 2020 | An investigator-initiated phase 2 clinical trial of Redasemtide in patients with DEB has been completed. |
| June 2020 | Established a new R&D base, “StemRIM Institute of Regeneration-Inducing Medicine, Osaka University”. |
| Sep. 2020 | The grant project titled 'Development of Therapeutics for Novel Coronavirus Infection (COVID-19) - Third Call' has been awarded by AMED (Japan Agency for Medical Research and Development). |
| Nov. 2020 | An investigator-initiated phase 2 clinical trial of Redasemtide in patients with Osteoarthritis of the knees has started at Hirosaki University. |
| Nov. 2020 | An investigator-initiated phase 2 clinical trial of Redasemtide in patients with Chronic Liver Disease has started at Niigata University. |
| Feb. 2021 | A trilateral research agreement has been signed between Shiseido Co., Ltd., Osaka University, for anti-aging research project related to the skin. |
| July 2022 | An additional investigator-initiated phase 2 clinical trial of Redasemtide in patients with DEB has started. |
| Mar. 2023 | A global phase 2b clinical trial of Redasemtide in patients with Acute Ischemic Stroke has started at Japan and North America. |
